Molecular Pathogenesis of Liver Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 261
Special Issue Editor
Interests: the molecular pathogenesis of non-alcoholic fatty liver; alcohol-associated liver-disease-related liver cancer development and progression; hepatocellular carcinoma; cholangiocarcinoma
Special Issue Information
Dear Colleagues,
Liver cancers, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), have an overall 5-year survival rate of 7–20%, representing one of the most deadly malignant tumors. While liver cancers may be cured, if not recurrent, by the surgical resection of removing malignant tumors completely at the early stage, liver cancers are generally diagnosed at the late stage due to a lack of obvious symptoms early on. Many multikinase inhibitors and immune checkpoint inhibitors have been approved for HCC treatments, but the overall 5-year survival of HCC patients has not significantly improved. Systemic chemotherapy (cisplatin and gemcitabine) and immune checkpoint inhibitors are potential treatments for CCA patients if CCA tumors are not resectable. Unfortunately, the 5-year survival of CCA patients is not significantly improved by these treatments, either. Under these circumstances, we still need to improve the treatments for liver cancer patients through understanding the molecular pathogenesis of these deadly diseases or by developing early detection markers. This Special Edition of Cancers is proposed to update the readers on the molecular pathogenesis of liver cancers regarding different etiologies, early detection markers, and potentially preclinical treatments.
Dr. Chiung-Kuei Huang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hepatocellular carcinoma
- cholangiocarcinoma
- bile duct cancer
- molecular pathogenesis
- therapeutic target
- early detection marker
